share_log

8-K: eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

8-K: eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

8-K:Effector Therapeutics公佈2024年第一季度財務業績並提供公司最新情況
美股sec公告 ·  05/09 16:15
Moomoo AI 已提取核心訊息
On May 9, 2024, eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter ending March 31, 2024, and provided a corporate update. The company reported progress in its zotatifin program, including the completion of the ZF doublet dose escalation and ongoing dose escalation in the ZFA triplet, with the recommended phase 2 dose (RP2D) expected in the second half of 2024. eFFECTOR also highlighted a median progression-free survival (mPFS) of 7.4 months in heavily pre-treated patients within the ZFA triplet cohort. Despite disappointing results from the KICKSTART trial in NSCLC, the company remains committed to advancing its pipeline, including continuing investigator-sponsored trials of zotatifin in ER+ breast cancer and tomivosertib in AML. The company also completed a registered...Show More
On May 9, 2024, eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter ending March 31, 2024, and provided a corporate update. The company reported progress in its zotatifin program, including the completion of the ZF doublet dose escalation and ongoing dose escalation in the ZFA triplet, with the recommended phase 2 dose (RP2D) expected in the second half of 2024. eFFECTOR also highlighted a median progression-free survival (mPFS) of 7.4 months in heavily pre-treated patients within the ZFA triplet cohort. Despite disappointing results from the KICKSTART trial in NSCLC, the company remains committed to advancing its pipeline, including continuing investigator-sponsored trials of zotatifin in ER+ breast cancer and tomivosertib in AML. The company also completed a registered direct financing in January 2024, raising $15.0 million and extending its cash runway into the first quarter of 2025. Financially, eFFECTOR reported a decrease in R&D expenses compared to the same quarter in the previous year and a slight increase in G&A expenses. The net loss for the quarter was $8.8 million, or $2.16 per share, compared to a net loss of $10.0 million, or $5.96 per share for the same period in 2023.
2024年5月9日,處於臨床階段的生物製藥公司Effector Therapeutics, Inc. 公佈了截至2024年3月31日的第一季度財務業績,並提供了公司最新情況。該公司報告了其佐他替芬計劃的進展,包括完成採埃孚雙聯劑量遞增和ZFA三聯劑量持續增加,推薦的2期劑量(RP2D)預計將在2024年下半年推出。Effector還強調了ZFA三聯隊列中經過大量預治療的患者的中位無進展存活率(MPF)爲7.4個月。儘管NSCLC的KICKSTART試驗結果令人失望,但該公司仍致力於推進其研發進程,包括繼續由研究者贊助的佐他替芬治療ER+乳腺癌和tomivosertib用於反洗錢的試驗。該公司還...展開全部
2024年5月9日,處於臨床階段的生物製藥公司Effector Therapeutics, Inc. 公佈了截至2024年3月31日的第一季度財務業績,並提供了公司最新情況。該公司報告了其佐他替芬計劃的進展,包括完成採埃孚雙聯劑量遞增和ZFA三聯劑量持續增加,推薦的2期劑量(RP2D)預計將在2024年下半年推出。Effector還強調了ZFA三聯隊列中經過大量預治療的患者的中位無進展存活率(MPF)爲7.4個月。儘管NSCLC的KICKSTART試驗結果令人失望,但該公司仍致力於推進其研發進程,包括繼續由研究者贊助的佐他替芬治療ER+乳腺癌和tomivosertib用於反洗錢的試驗。該公司還於2024年1月完成了註冊的直接融資,籌集了1,500萬美元,並將其現金流延至2025年第一季度。財務方面,Effector報告稱,與去年同期相比,研發費用有所減少,併購費用略有增加。該季度的淨虧損爲880萬美元,合每股虧損2.16美元,而2023年同期的淨虧損爲1,000萬美元,合每股虧損5.96美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息